Renal impairment can increase tadalafil systemic exposure, so current U.S. labeling modifies how the drug is framed as kidney function declines. The effect is not one universal renal rule: the label differs according to whether tadalafil is being used as needed for erectile dysfunction, once daily for ED or BPH, or in a pulmonary arterial hypertension product context.
Clinical pharmacology studies provide the PK rationale. Current CIALIS labeling reports approximately doubled tadalafil AUC in subjects with creatinine clearance from 30 to 80 mL/min, while end-stage renal disease on hemodialysis produced still greater exposure; hemodialysis contributed negligibly to tadalafil or metabolite elimination.
This page explains those label-defined categories without turning them into individualized renal dosing advice. Broader sources of exposure variability belong on the tadalafil PK variability page, while general dose frameworks belong on the tadalafil dosage page.
The most important interpretive point is that the same active drug appears in several labeled treatment frameworks. CIALIS labeling for ED and BPH does not use the same renal instructions as ADCIRCA or TADLIQ labeling for pulmonary arterial hypertension.
The thresholds are also expressed as creatinine clearance, or CrCl, rather than as a generic statement such as mild, moderate or severe kidney disease. Exact renal-function terminology should therefore be preserved when reading the label.
The table below summarizes current U.S. product and regimen wording as regulatory context rather than as a personalized dosing plan.
| Product / regimen | Renal context | Current label framework |
|---|---|---|
| CIALIS — ED as needed | CrCl 30–50 mL/min | Start 5 mg not more than once daily; maximum 10 mg not more than once every 48 hours |
| CIALIS — ED as needed | CrCl <30 mL/min or hemodialysis | Maximum 5 mg not more than once every 72 hours |
| CIALIS — ED once daily | CrCl <30 mL/min or hemodialysis | Once-daily use not recommended |
| CIALIS — BPH or ED/BPH once daily | CrCl 30–50 mL/min | Start 2.5 mg once daily; increase to 5 mg may be considered based on individual response |
| CIALIS — BPH or ED/BPH once daily | CrCl <30 mL/min or hemodialysis | Once-daily use not recommended |
| ADCIRCA — PAH | CrCl 51–80 or 31–50 mL/min | Start 20 mg once daily; increase to 40 mg once daily based on individual tolerability |
| ADCIRCA — PAH | CrCl <30 mL/min or hemodialysis | Avoid use |
| TADLIQ — PAH oral suspension | Mild or moderate renal impairment | Start 20 mg (5 mL) once daily; increase to 40 mg (10 mL) once daily based on individual tolerability |
| TADLIQ — PAH oral suspension | Severe renal impairment | Avoid use |
Tadalafil is not best understood as a drug that is simply excreted unchanged through the kidneys. It is extensively metabolized, and current labeling describes excretion predominantly as metabolites, with a greater proportion recovered in feces than urine.
Nevertheless, controlled pharmacokinetic studies show that systemic tadalafil exposure rises when renal function is impaired. The empirical PK finding matters more than assuming that limited urinary recovery of the parent drug would make kidney function irrelevant.
For the broader relationship between AUC, Cmax and systemic exposure, see the tadalafil exposure page.
| Concept | Renal-impairment relevance |
|---|---|
| Tadalafil metabolism | Parent drug is extensively metabolized |
| Excretion | Predominantly as metabolites rather than unchanged tadalafil |
| Renal impairment | Still associated with increased systemic tadalafil exposure |
| Clinical consequence | Product labels modify use according to renal function and indication |
CIALIS and PAH tadalafil labels express their renal thresholds using creatinine clearance in mL/min. That is more specific than simply stating that a patient has chronic kidney disease or an abnormal kidney laboratory result.
A renal value from another calculation should not automatically be substituted into a CrCl-based label threshold without appropriate clinical interpretation. The purpose of this page is therefore to preserve the renal categories as written rather than provide a calculator for individual treatment decisions.
This distinction is especially important around boundary values because different tadalafil product contexts do not use identical category wording.
| Term | How it is used here |
|---|---|
| CrCl | Creatinine clearance; the renal metric used in current tadalafil prescribing instructions |
| mL/min | Unit used for label thresholds |
| Kidney disease | Broader clinical concept that does not by itself specify the label category |
| Individual renal assessment | Requires appropriate clinical interpretation rather than a page-level dosing calculation |
For as-needed ED use, current CIALIS labeling provides explicit instructions when creatinine clearance is 30 to 50 mL/min. It gives a 5 mg starting dose not more than once per day and limits the maximum to 10 mg not more than once every 48 hours.
When creatinine clearance is below 30 mL/min or the patient is receiving hemodialysis, the label restricts use further to a maximum of 5 mg not more than once every 72 hours. This is a label-level framework rather than a recommendation for an individual reader to select or change a dose.
The general intermittent-treatment context belongs on the as-needed tadalafil page.
| CIALIS as-needed renal category | Current labeling |
|---|---|
| CrCl 30–50 mL/min | 5 mg starting dose not more than once daily; maximum 10 mg every 48 hours |
| CrCl <30 mL/min | Maximum 5 mg every 72 hours |
| Hemodialysis | Maximum 5 mg every 72 hours |
The once-daily ED framework is not simply the as-needed renal table repeated at a smaller tablet strength. Current CIALIS labeling states that once-daily use for ED is not recommended when creatinine clearance is below 30 mL/min or in patients on hemodialysis.
The rationale stated in the warnings section includes increased tadalafil exposure, limited clinical experience and the inability to meaningfully influence tadalafil clearance through dialysis.
The clinical distinction between continuous and intermittent tadalafil exposure is covered more broadly on the daily tadalafil page.
| Once-daily ED renal context | Label position |
|---|---|
| CrCl <30 mL/min | Once-daily CIALIS not recommended |
| Hemodialysis | Once-daily CIALIS not recommended |
| Reason stated in labeling | Higher exposure, limited experience and negligible ability of dialysis to alter clearance |
Current CIALIS labeling separately addresses once-daily use for BPH and for patients with both ED and BPH. With creatinine clearance from 30 to 50 mL/min, the label starts the framework at 2.5 mg once daily and states that an increase to 5 mg may be considered based on individual response.
When creatinine clearance is below 30 mL/min or the patient is on hemodialysis, once-daily CIALIS for BPH or ED/BPH is not recommended. This differs from the restricted intermittent framework that remains described for as-needed ED use.
The indications themselves are explained on the BPH page and the combined ED/BPH page.
| Once-daily BPH / ED+BPH context | Current labeling |
|---|---|
| CrCl 30–50 mL/min | 2.5 mg once daily initially; increase to 5 mg may be considered based on individual response |
| CrCl <30 mL/min | Once-daily use not recommended |
| Hemodialysis | Once-daily use not recommended |
As-needed tadalafil creates intermittent exposure, whereas daily administration produces repeated and continuous plasma exposure. Current labeling therefore does not handle severe renal impairment identically across those regimens.
For severe renal impairment or hemodialysis, the as-needed ED label retains a tightly restricted intermittent framework, while once-daily ED and BPH-related use is not recommended. The difference should be read as a regimen-specific regulatory decision rather than proof that one tablet strength is inherently safe or unsafe.
This is one reason a renal page must preserve both indication and regimen instead of listing isolated milligram values.
| Framework | Severe renal impairment / hemodialysis |
|---|---|
| ED as needed | Restricted intermittent use remains described in the label |
| ED once daily | Not recommended |
| BPH / ED+BPH once daily | Not recommended |
ADCIRCA is a tadalafil product labeled for pulmonary arterial hypertension, so its dose and renal instructions should not be copied from the CIALIS ED/BPH label. Current ADCIRCA labeling defines mild renal impairment as creatinine clearance 51 to 80 mL/min and moderate impairment as 31 to 50 mL/min.
For those mild or moderate categories, the label begins at 20 mg once daily and allows an increase to 40 mg once daily based on individual tolerability. In severe renal impairment, defined as creatinine clearance below 30 mL/min and in the hemodialysis context, ADCIRCA should be avoided.
The PAH indication itself belongs on the tadalafil for pulmonary arterial hypertension page, while brand-specific product information belongs on the Adcirca page.
| ADCIRCA renal category | Current PAH label framework |
|---|---|
| Mild — CrCl 51–80 mL/min | Start 20 mg once daily; increase to 40 mg once daily based on individual tolerability |
| Moderate — CrCl 31–50 mL/min | Start 20 mg once daily; increase to 40 mg once daily based on individual tolerability |
| Severe — CrCl <30 mL/min | Avoid use |
| Hemodialysis | Avoid use |
TADLIQ is tadalafil oral suspension labeled for pulmonary arterial hypertension. Its current renal-impairment instructions parallel the PAH tablet framework while expressing the dose in both milligrams and milliliters.
For mild or moderate renal impairment, current TADLIQ labeling starts at 20 mg, or 5 mL, once daily and allows an increase to 40 mg, or 10 mL, once daily based on individual tolerability. In severe renal impairment, the label says to avoid TADLIQ because of increased exposure, limited clinical experience and the inability to influence clearance through dialysis.
The formulation itself is covered on the TADLIQ product page.
| TADLIQ renal context | Current label framework |
|---|---|
| Mild or moderate renal impairment | 20 mg (5 mL) once daily initially; may increase to 40 mg (10 mL) once daily based on tolerability |
| Severe renal impairment | Avoid use |
| Rationale for severe impairment wording | Increased tadalafil AUC, limited clinical experience and negligible ability of dialysis to influence clearance |
CIALIS, ADCIRCA and TADLIQ contain the same active drug but belong to different product and indication frameworks. A milligram value taken from the PAH label should therefore not be inserted into ED or BPH guidance, and the reverse is also true.
PAH products use substantially different labeled treatment doses and define their renal categories within that PAH framework. CIALIS instead separates as-needed ED, daily ED and daily BPH/ED+BPH use.
The active ingredient is shared, but indication-specific evidence and labeling determine how renal impairment is handled.
| Context | Why it must remain separate |
|---|---|
| CIALIS — ED/BPH | Regimen and indication-specific renal instructions |
| ADCIRCA — PAH | PAH-specific dosing and renal categories |
| TADLIQ — PAH | PAH-specific renal framework plus oral-suspension formulation |
| Same active ingredient | Does not make product-label dose frameworks interchangeable |
Current CIALIS labeling reports that after single tadalafil doses of 5 to 10 mg, systemic exposure measured by AUC approximately doubled in subjects with creatinine clearance from 30 to 80 mL/min compared with subjects with normal renal function.
In end-stage renal disease on hemodialysis, the same label reports approximately a two-fold increase in Cmax and a 2.7- to 4.8-fold increase in AUC following single 10 mg or 20 mg tadalafil doses. These are study findings used to explain the renal restrictions, not a formula for calculating an individual person's tadalafil concentration.
The meaning of integrated systemic exposure belongs in greater depth on the tadalafil AUC page.
| Renal PK context in current CIALIS label | Observed effect |
|---|---|
| CrCl 30–80 mL/min | Tadalafil AUC approximately doubled |
| ESRD on hemodialysis | Cmax approximately doubled |
| ESRD on hemodialysis | AUC approximately 2.7- to 4.8-fold higher after the studied 10 mg or 20 mg doses |
Current ADCIRCA and TADLIQ pharmacokinetic sections likewise report approximately doubled tadalafil AUC in mild or moderate renal impairment. In subjects with end-stage renal disease on hemodialysis, they report approximately doubled Cmax and AUC about 2.7 to 4.1 times as high following the studied single doses.
The precise upper AUC multiple in the current PAH labels is therefore not identical to the 4.8-fold upper value reported in the current CIALIS renal section. These product-specific summaries should be quoted in their own label context rather than averaged or silently harmonized.
The consistent conclusion across the labels is more important than forcing one pooled number: renal impairment can meaningfully increase tadalafil systemic exposure.
| Current label | Mild/moderate renal impairment | ESRD / hemodialysis |
|---|---|---|
| CIALIS | AUC approximately 2× in CrCl 30–80 mL/min | Cmax ~2×; AUC 2.7–4.8× in the reported studies |
| ADCIRCA | AUC approximately 2× in CrCl 31–80 mL/min | Cmax ~2×; AUC 2.7–4.1× in the reported studies |
| TADLIQ | AUC approximately 2× in mild/moderate renal impairment | Cmax ~2×; AUC 2.7–4.1× in the reported studies |
Different current tadalafil labels summarize the end-stage renal disease data with slightly different upper AUC multiples. That is a reason to preserve the cited product label rather than create a synthetic average that appears nowhere in official prescribing information.
All of the labels point in the same clinical direction — substantially increased exposure in severe renal dysfunction — so there is no need to manufacture false precision. Product-specific wording is particularly important on a site that separately covers CIALIS, ADCIRCA and TADLIQ.
The broader reasons exposure can differ among populations belong on the PK variability page.
| Approach | Why |
|---|---|
| Quote each current label in its own context | Preserves the source-specific PK summary |
| Average the CIALIS and PAH AUC ranges | Not supported by labeling |
| Use one product's renal instructions for every tadalafil indication | Incorrect because label frameworks differ |
Current tadalafil labeling reports that hemodialysis performed 24 to 30 hours after dosing contributed negligibly to tadalafil or metabolite elimination. The same principle appears in the rationale for avoiding or restricting certain tadalafil regimens in severe renal impairment.
This means dialysis should not be viewed as a reliable way to reverse tadalafil exposure after administration. The labels explicitly cite the lack of ability to influence clearance through dialysis when explaining restrictions in severe renal dysfunction.
Tadalafil clearance as a pharmacokinetic concept is explained separately on the tadalafil clearance page.
| Dialysis question | Current-label finding |
|---|---|
| Does hemodialysis substantially remove tadalafil? | No |
| Study timing | Dialysis performed 24–30 hours after the dose |
| Effect on tadalafil / metabolite elimination | Negligible |
| Label relevance | Part of the rationale for restrictions in severe renal impairment |
The renal PK findings are not limited to the parent tadalafil molecule. Current labels report that exposure to total methylcatechol, including unconjugated and glucuronide forms, was approximately 2 to 4 times higher in subjects with renal impairment than in those with normal renal function.
Current tadalafil pharmacology describes these metabolites as not expected to be pharmacologically active at the observed concentrations. Their increased exposure nevertheless forms part of the overall ADME picture in renal dysfunction.
This page keeps that observation in renal context rather than turning it into a separate claim about clinical activity.
| PK component | Renal finding |
|---|---|
| Parent tadalafil | AUC increases with renal impairment |
| Total methylcatechol | Approximately 2- to 4-fold higher exposure |
| Metabolite pharmacologic activity | Not expected to be clinically active at observed concentrations |
Tadalafil undergoes extensive metabolism before elimination. PAH labeling reports that following tadalafil administration, drug-related material is excreted predominantly as metabolites, mainly in feces and to a lesser extent in urine.
That elimination pattern and the renal-impairment PK findings are not contradictory. Renal dysfunction can alter overall disposition and exposure even when the parent drug is not primarily cleared unchanged into urine.
The complete ADME pathway belongs on the tadalafil pharmacokinetics page.
| Elimination feature | Current PAH-label context |
|---|---|
| Fecal recovery | Approximately 61% of the dose, predominantly as metabolites |
| Urinary recovery | Approximately 36% of the dose, predominantly as metabolites |
| Interpretation | Renal impairment can still increase tadalafil exposure despite extensive metabolism |
Current CIALIS labeling describes a clinical pharmacology study involving 28 subjects in which back pain was a limiting adverse event in men with creatinine clearance from 30 to 50 mL/min who received tadalafil 10 mg. At 5 mg, the incidence and severity of back pain were not significantly different from those in the general population.
This observation helps explain why renal impairment is not only an abstract AUC issue: altered exposure can affect tolerability. However, the small study should not be used to predict whether a particular patient will or will not experience back pain.
The general adverse-reaction profile remains on the tadalafil side-effects page.
| Renal-study feature | Current CIALIS label |
|---|---|
| Study size | N=28 |
| CrCl group | 30–50 mL/min |
| Tadalafil 10 mg | Back pain reported as a limiting adverse event |
| Tadalafil 5 mg | Back-pain incidence/severity not significantly different from the general population |
Kidney impairment is clinically important, but current tadalafil labels do not classify renal impairment itself as one universal formal contraindication. Instead, they use dose/frequency limitations, not-recommended language or avoid-use language according to product, indication and renal category.
This distinction matters because 'contraindicated,' 'not recommended' and 'avoid use' should not be treated as interchangeable regulatory terms. For example, current CIALIS retains restricted as-needed ED use even in severe renal impairment, while once-daily CIALIS is not recommended and PAH products instruct clinicians to avoid use in severe impairment.
Formal tadalafil contraindications are covered separately on the tadalafil contraindications page.
| Renal statement | Accurate? |
|---|---|
| All kidney disease is a formal tadalafil contraindication | No |
| Renal impairment can increase tadalafil exposure | Yes |
| Current renal restrictions vary by regimen and product | Yes |
| Severe renal impairment is handled identically in CIALIS and PAH labeling | No |
Kidney function is one documented determinant of tadalafil exposure, but it is not the only one. CYP3A interactions, repeated dosing, pulmonary-hypertension population pharmacokinetics and other patient factors can also change systemic exposure.
This page owns the renal evidence and renal-specific labeling consequences. It deliberately does not become a general catalog of every reason tadalafil AUC or Cmax can vary.
That broader framework belongs on the tadalafil pharmacokinetic variability page.
| Question | Best destination |
|---|---|
| What happens to tadalafil exposure in renal impairment? | This renal-impairment page |
| Why can tadalafil exposure vary in general? | PK variability |
| What does AUC mean? | Tadalafil AUC |
| How is tadalafil removed from the body? | Tadalafil clearance |
The active ingredient tadalafil can appear under different brand and formulation contexts. A renal instruction found in an ADCIRCA or TADLIQ PAH label should not be assumed to describe CIALIS treatment for ED or BPH.
Likewise, a CIALIS as-needed ED renal limit should not be applied to a PAH regimen simply because both products contain tadalafil. Indication, formulation and product labeling must remain linked.
This is particularly important when reviewing medication lists that show only the active ingredient without the treatment indication.
| Product | Primary label context relevant here |
|---|---|
| CIALIS | ED, BPH and ED/BPH |
| ADCIRCA | Pulmonary arterial hypertension |
| TADLIQ | Pulmonary arterial hypertension oral suspension |
| Generic tadalafil | Interpret according to the specific approved product labeling and indication |
A useful renal review starts by identifying more than the diagnosis 'kidney disease.' The relevant label interpretation depends on the renal metric, product, indication and tadalafil regimen.
The checklist below is designed to prevent ED, BPH and PAH instructions from being mixed together rather than to select an individualized dose.
| Check | Why it matters |
|---|---|
| What is the renal-function category? | Current labels use creatinine-clearance thresholds |
| Which tadalafil product is involved? | CIALIS, ADCIRCA and TADLIQ have different indication frameworks |
| What is the indication? | ED, BPH/ED+BPH and PAH use different renal instructions |
| Is CIALIS being used as needed or once daily? | Severe renal impairment is handled differently by regimen |
| Is the patient receiving hemodialysis? | Dialysis contributes negligibly to tadalafil elimination and changes label restrictions |
| Are isolated PK numbers being used as a dose calculator? | AUC and Cmax study findings explain the label but do not provide personalized dosing formulas |
| Is a PAH renal dose being copied into an ED/BPH context? | Product-specific renal frameworks should not be interchanged |
Renal impairment can meaningfully increase tadalafil systemic exposure. Current CIALIS labeling reports approximately doubled AUC with creatinine clearance from 30 to 80 mL/min and substantially higher exposure in end-stage renal disease on hemodialysis; dialysis itself contributes negligibly to tadalafil or metabolite elimination.
The resulting label framework depends on the indication and regimen. CIALIS as-needed ED, CIALIS once-daily ED, CIALIS for BPH/ED+BPH and PAH products such as ADCIRCA or TADLIQ do not use one interchangeable set of renal instructions.
The safest way to interpret renal labeling is therefore to preserve product, indication, regimen and CrCl category together. PK findings such as higher AUC explain why restrictions exist, but they should not be converted into a personalized renal dosing formula.
Yes. Current tadalafil labeling reports increased systemic exposure as renal function declines. The clinical implications depend on the product, indication, regimen and creatinine-clearance category.
Yes. Current CIALIS pharmacokinetic data report approximately doubled tadalafil AUC in subjects with creatinine clearance from 30 to 80 mL/min, with still greater exposure in end-stage renal disease on hemodialysis.
Current CIALIS labeling reports roughly a two-fold AUC increase at creatinine clearance 30 to 80 mL/min. In end-stage renal disease on hemodialysis, Cmax approximately doubled and AUC was reported as 2.7 to 4.8 times higher after the studied single doses.
Current ADCIRCA and TADLIQ labels summarize the end-stage renal disease study with an AUC range of approximately 2.7 to 4.1 times normal, while the current CIALIS label reports an upper value of 4.8. These product-label summaries should be preserved separately rather than averaged into a new number.
Not effectively. Current labeling states that hemodialysis performed 24 to 30 hours after dosing contributed negligibly to tadalafil or metabolite elimination.
Renal impairment is not one blanket formal tadalafil contraindication. Current labels instead use regimen-specific dose and frequency limits, not-recommended wording or avoid-use wording depending on the product and severity of renal impairment.
Current CIALIS labeling states a 5 mg starting dose not more than once per day and a maximum of 10 mg not more than once every 48 hours. This is label information, not individualized dosing advice.
Current CIALIS labeling limits as-needed use to a maximum of 5 mg not more than once every 72 hours in patients with creatinine clearance below 30 mL/min or end-stage renal disease on hemodialysis.
No. Current CIALIS labeling states that once-daily use is not recommended when creatinine clearance is below 30 mL/min or in patients on hemodialysis.
For BPH or ED/BPH with creatinine clearance 30 to 50 mL/min, current labeling uses a lower once-daily starting framework and permits an increase based on individual response. With creatinine clearance below 30 mL/min or hemodialysis, once-daily use is not recommended.
No. Both contain tadalafil, but CIALIS is labeled in ED/BPH contexts while ADCIRCA is a PAH product with a separate renal dosing framework.
Current ADCIRCA labeling defines mild impairment as creatinine clearance 51 to 80 mL/min and moderate impairment as 31 to 50 mL/min. It starts the PAH framework at 20 mg once daily and permits an increase to 40 mg based on individual tolerability.
Current ADCIRCA labeling says to avoid use when creatinine clearance is below 30 mL/min and in the hemodialysis context because of increased tadalafil exposure, limited clinical experience and inability to meaningfully influence clearance through dialysis.
Yes. Current TADLIQ labeling uses a PAH renal framework similar to ADCIRCA: 20 mg (5 mL) once daily initially in mild or moderate impairment with possible increase based on tolerability, and avoidance in severe renal impairment.
The regimens create different exposure patterns. Current labeling retains a restricted intermittent as-needed framework in severe renal impairment but does not recommend once-daily CIALIS in that renal category.
Renal impairment is associated with higher tadalafil AUC, meaning greater systemic exposure over time. The exact clinical implications depend on the regimen and product label rather than on AUC alone.
Yes. Current labeling reports approximately 2- to 4-fold higher exposure to total methylcatechol forms in subjects with renal impairment compared with subjects with normal renal function.
No. Tadalafil is extensively metabolized, and PAH labeling describes drug-related material as being excreted predominantly as metabolites, mainly in feces and to a lesser extent in urine. Renal impairment can nevertheless substantially increase tadalafil exposure.
Higher exposure can affect tolerability. Current CIALIS labeling describes a small renal pharmacology study in which back pain was a limiting adverse event at tadalafil 10 mg in men with creatinine clearance 30 to 50 mL/min, while the 5 mg findings differed.
Current tadalafil labels express their renal categories using creatinine clearance in mL/min. A different renal estimate should not automatically be substituted for the label's CrCl categories without appropriate clinical interpretation.